Evaluation of planned foveal detachment technique for rapid resolution of resistant diabetic macular oedema

Purpose: Diabetic macular edema (DME) is the main cause of the diminution of vision in diabetic patients. There are many pharmacological and surgical modalities used for the treatment of DME, however, the refractory DME still represents a challenge, because of the associated lower success rates. Aim of the work: The evaluation of effectiveness and safety of planned foveal detachment technique in rapid resolution of DME in cases resistant to anti Vascular Endothelial Growth Factor (Anti VEGF) therapy as regards macular anatomy and function. Patients and methods: This study included 36 patients with diffuse or cystoid DME despite undergoing anti-VEGF therapy at least 6 times and recruited from Mansoura ophthalmic center. All cases were subjected to taking full history and full ophthalmological examination including assessment by spectral- domain OCT. All the included cases underwent planned foveal detachment technique, and follow up was done at one-week, one month, 3 months, and 6 months post- operative. Results : There was a statistically significant post-operative improvement in the best-corrected visual acuity (BCVA) at 1 week, 1 month, and 3 months, as compared with the preoperative values. There was a statistically significant post-operative reduction in the central foveal thickness (CFT) at 1 week, 1 month, 3 months, and 6 months compared to preoperative values. Conclusion : Planned foveal detachment technique was an effective technique that is associated with relatively rapid improvement of BCVA and CFT among cases with DME who were resistant to treatment by Anti VEGF.

[1]  R. Gallemore,et al.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options , 2021, Cells.

[2]  Ling Qin,et al.  Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis , 2020, Annals of translational medicine.

[3]  A. Loewenstein,et al.  The Role of Steroids in the Management of Diabetic Macular Edema , 2019, Ophthalmic Research.

[4]  A. A. Abdel Hadi Evaluation of Vitrectomy with Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema with or without Vitreomacular Interface Abnormality , 2018, Journal of ophthalmology.

[5]  Y. Morizane,et al.  Planned Foveal Detachment Technique for the Resolution of Diabetic Macular Edema Resistant to Anti-Vascular Endothelial Growth Factor Therapy. , 2017, Retina.

[6]  J. Ulrich,et al.  Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Nontractional Diabetic Macular Edema , 2017, The open ophthalmology journal.

[7]  T. Hong,et al.  Diabetic macular oedema: pathophysiology, management challenges and treatment resistance , 2016, Diabetologia.

[8]  A. Ho,et al.  Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. , 2016, American journal of ophthalmology.

[9]  T. Wong,et al.  Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss , 2015, Eye and Vision.

[10]  Y. Morizane,et al.  Planned foveal detachment technique for the resolution of diffuse diabetic macular edema , 2015, Japanese Journal of Ophthalmology.

[11]  Arup Das,et al.  Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. , 2015, Ophthalmology.

[12]  W. Amoaku,et al.  A review of therapies for diabetic macular oedema and rationale for combination therapy , 2015, Eye.

[13]  Walter T Ambrosius,et al.  The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. , 2014, Ophthalmology.

[14]  Igor Kozak,et al.  External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[15]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[16]  Aydin Macin,et al.  Quantitative Assessment of Photoreceptor Layer in Eyes with Resolved Edema after Pars Plana Vitrectomy with Internal Limiting Membrane Removal for Diabetic Macular Edema , 2011, Ophthalmologica.

[17]  Jennifer K. Sun,et al.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. , 2011, Ophthalmology.

[18]  N. Bressler,et al.  Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. , 2010, Ophthalmology.

[19]  A. Tsujikawa,et al.  Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[20]  S. Binder,et al.  Vitrectomy for persistent diffuse diabetic macular edema. , 2005, American journal of ophthalmology.

[21]  N. Ozaki,et al.  Triamcinolone Acetonide Facilitates Removal of the Epiretinal Membrane and Separation of the Residual Vitreous Cortex in Highly Myopic Eyes with Retinal Detachment due to a Macular Hole , 2004, Ophthalmologica.

[22]  Nagahisa Yoshimura,et al.  Association between Hyperreflective Foci in the Outer Retina, Status of Photoreceptor Layer and Visual Acuity in Diabetic Macular Edema Running title: Hyperreflective foci, photoreceptor layer, and VA in DME , 2018 .

[23]  Y. Ogura,et al.  Management of diabetic macular edema in Japan: a review and expert opinion , 2017, Japanese Journal of Ophthalmology.

[24]  E. Uchino,et al.  Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[25]  R. Meirelles,et al.  Use of Optical Coherence Tomography (OCT) and Indirect Ophthalmoscopy in the Diagnosis of Macular Edema in Diabetic Patients , 2004, International Ophthalmology.